Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
|
|
RENOVIS INC (RNVS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/14/2008 |
8-K
| Quarterly results|
Docs:
|
"RENOVIS REPORTS FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS South San Francisco, California - March 14, 2008 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced financial results for the fourth quarter and year ended December 31, 2007. Revenue for the fourth quarter and the year ended December 31, 2007 was $1.3 million and $9.8 million, respectively, compared to $2.2 million and $10.4 million in the corresponding periods in 2006. All of the revenue earned in the year ended December 31, 2007 related to our collaboration with Pfizer Inc. to research, develop and commercialize small molecules that target the vanilloid receptor, or VR1. The decreas..." |
|
| 11/07/2007 |
8-K
| Quarterly results |
| 08/07/2007 |
8-K
| Quarterly results |
| 05/08/2007 |
8-K
| Quarterly results |
| 03/01/2007 |
8-K
| Quarterly results |
| 10/26/2006 |
8-K
| Quarterly results |
| 07/27/2006 |
8-K
| Quarterly results |
| 04/28/2006 |
8-K
| Quarterly results|
Docs:
|
"RENOVIS REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS South San Francisco, California - April 27, 2005 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for diseases and disorders in the areas of cytoprotection, pain and inflammation, today announced financial results for the first quarter ended March 31, 2006. Revenue for the quarter ended March 31, 2006 was $2.5 million, which included $2.2 million from our collaboration with Pfizer Inc to discover and develop VR1 antagonists for pain and other indications. This compares to first quarter 2005 revenue of $0.7 million from our collaboration with Genentech, Inc. in the areas of neurological disorders and anti-angiogenesis." |
|
| 02/24/2006 |
8-K
| Quarterly results|
Docs:
|
"RENOVIS REPORTS FOURTH QUARTER AND FULL YEAR 2005 FINANCIAL RESULTS South San Francisco, California - February 23, 2006 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for diseases and disorders in the areas of neuroprotection, pain and inflammation, today announced financial results for the fourth quarter and year ended December 31, 2005. Revenue for the quarter and year ended December 31, 2005 was $2.6 million and $6.6 million, which included $2.2 million and $4.4 million in revenue, respectively, from our collaboration with Pfizer, Inc. to discover and develop VR1 antagonists for pain and other indications. The remainder of our revenue during these periods as well as our total revenue of $0.7 million and $2.6 million for the quarter and ye..." |
|
| 10/28/2005 |
8-K
| Quarterly results|
Docs:
|
"RENOVIS REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS South San Francisco, California - October 27, 2005 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs to treat neurological diseases and disorders, today announced financial results for the third quarter and nine months ended September 30, 2005. Revenue for the quarter and nine months ended September 30, 2005 was $2.7 million and $4.0 million, respectively, compared with $0.7 million and $2.0 million for the corresponding periods in 2004. The revenue for each of the 2005 periods includes approximately $2.2 million that we recorded during the third quarter related to our collaboration with Pfizer, Inc. to discover and develop VR1 antagonists for pain and other indications. All other contract re..." |
|
|
|